Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | FASN | P49327 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881328 | 0.82 | L3MBTL1 (0.55) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14298343 | 0.80 | L3MBTL1 (0.54) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5203135 | 0.79 | NPC1 (0.47) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL15218659 | 0.77 | KDM4E (0.62) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL19699460 | 0.77 | L3MBTL1 (0.51) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL29141778 | 0.77 | NPC1 (0.55) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL6360506 | 0.76 | KDM4E (0.52) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL1464725 | 0.75 | CNR2 (0.56) | L3MBTL1POLBFASNMAPTCYP2C9 | |
| SCHEMBL28269774 | 0.75 | L3MBTL1 (0.49) | L3MBTL1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14667351 | 0.74 | ADORA1 (0.44) | L3MBTL1KMT2APOLBSMN1; SMN2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| CN-1751052-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-22 | — | — | CN | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | L3MBTL1 4225/4885KMT2A 1034/4885NPC1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.